Table 1. Characteristics of eligible studies for the association between the 1772 C/T polymorphism and cancer risk.
| First Author (Reference) | Year | Country | Ethnicity | Control Source | Cancer Type | Cases |
Controls |
HWE | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC | CT | TT | CC | CT | TT | |||||||
| Tanimoto | 2003 | Japan | Asian | PB | Head and neck squamous cell carcinoma | 45 | 10 | 0 | 98 | 12 | 0 | 0.545 |
| Kuwai | 2004 | Japan | Asian | PB | Colorectal cancer | 100 | 0 | 0 | 89 | 11 | 0 | 0.561 |
| Ling | 2005 | China | Asian | PB | Esophogeal sqaumous cell carcinoma | 84 | 11 | 0 | 93 | 11 | 0 | 0.569 |
| Kim | 2008 | Korea | Asian | HB | Breast cancer | 81 | 8 | 1 | 93 | 9 | 0 | 0.641 |
| Lee | 2008 | Korea | Asian | PB | Breast cancer | 1207 | 119 | 6 | 1245 | 123 | 1 | 0.25 |
| Nadaoka | 2008 | Japan | Asian | PB | Transitional cell carcinoma of bladder | 197 | 22 | 419 | 42 | 0.35 | ||
| Chen | 2009 | China | Asian | PB | Oral cancer | 163 | 10 | 1 | 334 | 13 | 0 | 0.722 |
| Li | 2009 | China | Asian | PB | Gastric cancer | 83 | 4 | 0 | 93 | 13 | 0 | 0.501 |
| Naidu | 2009 | Malaysia | Asian | PB | Breast cancer | 294 | 100 | 16 | 222 | 50 | 3 | 0.922 |
| Chai | 2010 | China | Asian | HB | Cervical cancer | 65 | 25 | 7 | 94 | 21 | 2 | 0.52 |
| Hsiao | 2010 | China | Asian | HB | Hepatocellular carcinoma | 94 | 8 | 0 | 334 | 13 | 0 | 0.722 |
| Kang | 2011 | Korea | Asian | PB | Colorectal cancer | 38 | 12 | 46 | 4 | |||
| Kim | 2011 | Korea | Asian | HB | Cervical cancer | 177 | 22 | 0 | 187 | 27 | 0 | 0.325 |
| Putra | 2011 | Japan | Asian | HB | Lung cancer | 74 | 9 | 0 | 98 | 12 | 0 | 0.545 |
| Wang | 2011 | China | Asian | HB | Pancreatic cancer | 209, (198) | 54 | 0 | 242 | 29 | 0 | 0.352 |
| Xu | 2011 | China | Asian | HB | Glioma | 121 | 27 | 2 | 135 | 14 | 1 | 0.354 |
| Li | 2012 | China | Asian | HB | Prostate cancer | 612 | 48 | 2 | 659 | 57 | 0 | 0.267 |
| Clifford | 2001 | UK | Caucasian | PB | Renal cell carcinoma | 30 | 5 | 0 | 110 | 27 | 6 | 0.018 |
| Ollerenshaw | 2004 | UK | Caucasian | PB | Renal cell carcinoma | 16 | 54 | 90 | 1 | 90 | 71 | <0.001, |
| Fransen | 2006 | Sweden | Caucasian | PB | Colorectal cancer | 167 | 28 | 3 | 213 | 43 | 2 | 0.916 |
| Konac | 2007 | Turkey | Caucasian | HB | Endometrial, ovarian, and cervical cancer | 48 | 40 | 14 | 68 | 37 | 2 | 0.229 |
| Orr-Urtreger | 2007 | Israel | Caucasian | PB | Prostate cancer | 287 | 99 | 16 | 217 | 80 | 3 | 0.137 |
| Horre´e | 2008 | Netherlands | Caucasian | PB | Endometrial cancer | 50 | 5 | 3 | 463 | 84 | 12 | 0.001 |
| Apaydin | 2008 | Turkey | Caucasian | PB | Breast cancer | 79 | 21 | 2 | 68 | 29 | 5 | 0.415 |
| Foley | 2009 | Ireland | Caucasian | PB | Prostate cancer | 65 | 30 | 0 | 175 | 13 | 0 | 0.623 |
| Muñoz-Guerra | 2009 | Spain | Caucasian | PB | Oral cancer | 57, | 6 | 7 | 113 | 27 | 8 | 0.001 |
| Konac | 2009 | Turkey | Caucasian | HB | Lung cancer | 110, | 31 | 0 | 111 | 43 | 2 | 0.335 |
| Knechtel | 2010 | Austrila | Caucasian | HB | Colorectal cancer | 291 | 77 | 1773 | 383 | >0.05 | ||
| Ruiz-Tovar | 2012 | Spian | Caucasian | PB | Pancreatic cancer | 47 | 1 | 11 | 116 | 28 | 8 | 0.002 |
| Kuo | 2012 | China | Caucasian | HB | Lung cancer | 153 | 94 | 38 | 216 | 73 | 11 | 0.132 |
| Alves | 2012 | Brazil | Caucasian | PB | Oral cancer | 0 | 1 | 39 | 0 | 85 | 3 | <0.001 |
| Zagouri | 2012 | Greece | Caucasian | HB | Breast cancer | 98 | 15 | 0 | 107 | 17 | 0 | 0.413 |
| Chau | 2005 | USA | Mixed | PB | Prostate cancer | 161 | 29 | 6 | 179 | 14 | 3 | <0.001 |
| Li | 2007 | USA | Mixed | PB | Prostate cancer | 818 | 209 | 14 | 175 | 13 | 0 | 0.623 |